Online inquiry

IVTScrip™ mRNA-Anti-TNF, ENIA11(Cap 0, 2-Thio-UTP, 30 nt-poly(A))   (CAT#: GTTS-WQ6941MR)

This product GTTS-WQ6941MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 0 & 2-Thio-UTP. It ecodes the monoclonal antibody that targets TNF gene. The antibody can be applied in Rheumatoid arthritis (RA), Ankylosing spondylitis (AS) research.
Specifications
Product type mRNA
Modified bases 2-Thio-UTP
5' Cap Cap 0
Species Homo sapiens
RefSeq NM_000594.4
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 7124
UniProt ID P01375
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-TNF, ENIA11(Cap 0, 2-Thio-UTP, 30 nt-poly(A)) (GTTS-WQ6941MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ12661MR IVTScrip™ mRNA-Anti-FZD1&FZD2&FZD5&FZD7&FZD8, OMP-18R5(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA OMP-18R5
GTTS-WQ8006MR IVTScrip™ mRNA-Anti-CD52, GZ-402668(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA GZ-402668
GTTS-WQ3554MR IVTScrip™ mRNA-Anti-MIF, BAX069(Cap 1, 2-Thio-UTP, 30 nt-poly(A)) mRNA BAX069
GTTS-WQ1042MR IVTScrip™ mRNA-Anti-MET, ABBV-399(Cap 1, 5-Methyl-CTP, 30 nt-poly(A)) mRNA ABBV-399
GTTS-WQ7618MR IVTScrip™ mRNA-Anti-CSF3R, G-CSF-Fc-PEG(Cap 1, 5-Methyl-CTP, 30 nt-poly(A)) mRNA G-CSF-Fc-PEG
GTTS-WQ11250MR IVTScrip™ mRNA-Anti-CD274, MEDI4736(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA MEDI4736
GTTS-WQ1071MR IVTScrip™ mRNA-Anti-SLAMF7, ABBV-838(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA ABBV-838
GTTS-WQ5850MR IVTScrip™ mRNA-Anti-CD40, CHIR-12,12(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA CHIR-12,12
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW